VYNE Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of -4394.08% compared to VYNE Therapeutics, Inc.'s net margin of --. VYNE Therapeutics, Inc.'s return on equity of -73.23% beat Palatin Technologies's return on equity of --.

VYNE Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 586.7%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than VYNE Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than VYNE Therapeutics, Inc..

VYNE Therapeutics, Inc. has a beta of 1.995, which suggesting that the stock is 99.496% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

VYNE Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VYNE Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

VYNE Therapeutics, Inc. quarterly revenues are $169K, which are larger than Palatin Technologies quarterly revenues of --. VYNE Therapeutics, Inc.'s net income of -$7.4M is higher than Palatin Technologies's net income of --. Notably, VYNE Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VYNE Therapeutics, Inc. is 47.48x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -4394.08% compared to VYNE Therapeutics, Inc.'s net margin of -3135.32%. VYNE Therapeutics, Inc.'s return on equity of -73.23% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

VYNE Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 586.7%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 59.09%. Given that VYNE Therapeutics, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe VYNE Therapeutics, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

VYNE Therapeutics, Inc. has a beta of 1.995, which suggesting that the stock is 99.496% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

VYNE Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VYNE Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

VYNE Therapeutics, Inc. quarterly revenues are $169K, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. VYNE Therapeutics, Inc.'s net income of -$7.4M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, VYNE Therapeutics, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VYNE Therapeutics, Inc. is 47.48x versus 40.36x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of -4394.08% compared to VYNE Therapeutics, Inc.'s net margin of 18.08%. VYNE Therapeutics, Inc.'s return on equity of -73.23% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

VYNE Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 586.7%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 42.63%. Given that VYNE Therapeutics, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe VYNE Therapeutics, Inc. is more attractive than Theravance Biopharma, Inc..

VYNE Therapeutics, Inc. has a beta of 1.995, which suggesting that the stock is 99.496% more volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.

VYNE Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VYNE Therapeutics, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

VYNE Therapeutics, Inc. quarterly revenues are $169K, which are smaller than Theravance Biopharma, Inc. quarterly revenues of $20M. VYNE Therapeutics, Inc.'s net income of -$7.4M is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, VYNE Therapeutics, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VYNE Therapeutics, Inc. is 47.48x versus 11.75x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -4394.08% compared to VYNE Therapeutics, Inc.'s net margin of --. VYNE Therapeutics, Inc.'s return on equity of -73.23% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

VYNE Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 586.7%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than VYNE Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than VYNE Therapeutics, Inc..

VYNE Therapeutics, Inc. has a beta of 1.995, which suggesting that the stock is 99.496% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

VYNE Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. VYNE Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

VYNE Therapeutics, Inc. quarterly revenues are $169K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. VYNE Therapeutics, Inc.'s net income of -$7.4M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, VYNE Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VYNE Therapeutics, Inc. is 47.48x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.